Trial Profile
Evaluation of renal function in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor (sunitinib or sorafenib)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Apr 2018
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 06 Apr 2018 New trial record